FirmaIQ
Org.nr 985 889 635 2017 → 2018 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2018 vs 2017

Shrank 16% on revenue, fresh owner capital

approved 2019-06-12; registry 2019-07-31; journal 2019 835877

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2018 with 2017 for LYTIX BIOPHARMA ASA. Revenue 14.15m NOK → 11.84m NOK (-16.3%). Net result -63.36m NOK → -61.52m NOK. Equity 11.79m NOK → 41.05m NOK.

On the constructive side: equity strengthened; cash rose; owners injected capital. Pressures included: revenue fell.

Net constructive year on the published lines.

At a glance

Scorecard

Revenue
14.15m NOK 11.84m NOK
-16.3%
Operating result
-77.86m NOK n/m
—
Net result
-63.36m NOK -61.52m NOK
+2.9%
Equity
11.79m NOK 41.05m NOK
+248.1%
Cash
34.96m NOK 49.62m NOK
+41.9%
Total assets
47.09m NOK 58.90m NOK
+25.1%

What improved

  • ↑

    Equity strengthened

    Book equity 11.79m NOK → 41.05m NOK (equity ratio 25.0% → 69.7%). Calculated

  • ↑

    Cash rose

    Bank deposits 34.96m NOK → 49.62m NOK (+41.9% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 11.79m NOK → 37.05m NOK (+25.26m NOK). Reported fact

What deteriorated

  • ↓

    Revenue fell

    Operating income / revenue moved from 14.15m NOK to 11.84m NOK (-16.3% YoY). Calculated